GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (LTS:0QCO) » Definitions » Loans Receivable

Pharming Group (LTS:0QCO) Loans Receivable : €0.0 Mil (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Pharming Group Loans Receivable?

Pharming Group's Loans Receivable for the quarter that ended in Dec. 2024 was €0.0 Mil.


Pharming Group Loans Receivable Historical Data

The historical data trend for Pharming Group's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Loans Receivable Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharming Group Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharming Group Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Pharming Group Loans Receivable Related Terms

Thank you for viewing the detailed overview of Pharming Group's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Traded in Other Exchanges
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines